Intravenous Tirofiban in Acute Non-cardioembolic Stroke: Preventing Early Neurological Deterioration – A Narrative Review
Iman Osman Abufatima1, Huzaifa Nawaz2, Rida Eman3, Iqra Yaseen4, Dr Bushra5, Maheen Munir6, Mirza Mohammad Ali Baig7, Muhammad Umar8, Yasar Sattar9, Hafiz Sohail Ashraf10
1University of medical Sciences and technology, khartoum, Sudan, 2Services Institute of Medical Sciences (SIMS), Ghaus-ul-Azam Jail Road, Lahore, Pakistan 54000, 3argodha Medical College, 4Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan, 5People University Of Medical And Health Science, Nawabshah, 6Liaquat University of Medical and Health Sciences Jamshoro, 7Islamic International Medical College, Riphah International University, Rawalpindi, Pakistan, 8Khairpur medical college, Khairpur mir's, Pakistan, 9Arnot Ogden Cardiology Elmira NY, 10Carle foundation Hospital Urbana Illinois
Objective:
To evaluate the clinical efficacy, safety, and therapeutic potential of intravenous tirofiban in preventing early neurological deterioration among patients with non-cardioembolic acute ischemic stroke.
Background:
Acute non-cardioembolic stroke, a major subtype of acute ischemic stroke (AIS), remains a leading global cause of disability and death. Although reperfusion therapies such as intravenous thrombolysis and mechanical thrombectomy have improved outcomes, many patients still experience early neurological deterioration (END). Current therapeutic options are limited by narrow time windows, hemorrhagic risk, and accessibility barriers, emphasizing the need for effective adjunctive strategies.
Design/Methods:
This narrative review synthesizes evidence from randomized controlled trials, observational cohorts, and meta-analyses assessing tirofiban’s pharmacological properties, clinical outcomes, and adverse event profile when used alone or in combination with thrombolysis or endovascular therapy.
Results:
Tirofiban, a non-peptide glycoprotein IIb/IIIa receptor antagonist, inhibits platelet aggregation and thrombus formation, thereby preventing re-occlusion and recurrent ischemia. Across multiple studies, intravenous tirofiban was associated with lower rates of END, improved 90-day modified Rankin Scale (mRS) scores, and reduced mortality without significantly increasing symptomatic intracranial hemorrhage. Patients with large-artery atherosclerosis derived particular benefit. However, heterogeneity in study design, dosing, and patient selection limits the generalizability of findings.
Conclusions:
Intravenous tirofiban demonstrates promise as an adjunctive therapy in acute non-cardioembolic stroke, showing potential to improve functional outcomes and reduce mortality with acceptable safety. Despite encouraging evidence, its role remains investigational. Large, multicenter randomized trials are needed to confirm efficacy, establish standardized protocols, and define its optimal integration into acute stroke management.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.